09/09/2025
We've achieved a medical milestone by becoming the first facility on Long Island to offer Carvykti, an advanced CAR–T cell therapy for patients with relapsed or refractory multiple myeloma, a type of blood cancer.
Socorro, a 62-year-old grandmother of six, was the first Northwell patient to receive this cutting-edge treatment in June 2025. This innovative treatment modifies a patient's own T-cells to target cancer cells, offering a new era of personalized care. “This new therapy has given me renewed hope because the back pain that plagued me for many years is fading, and I’m feeling stronger every day," said Socorro.
"What makes Carvykti different from previous multiple myeloma treatments is the mechanism of action," explained A. Samer Al-Homsi, MD, MBA, system chief of blood and marrow transplant and cellular therapy at the Northwell Cancer Institute. "It's one of these new treatments that leverage the power of the immune system to attack the cancer cells. It is not using medications or chemical substances — it's really directing the immune system of the patient to fight the cancer.”
🔗 https://bit.ly/42jigdy